Payment overview · 2025
General Payments
$685.54
24 reported records · 6 companies
Healthcare provider profile · identity verified
Parmveer Singh Bains
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · MADERA, CA · NPI 1578039665
Verified facts
What the public records show
CMS Open Payments records show Parmveer Singh Bains received $685.54 in general payments during 2025 across 24 reported records.
Stryker Corporation accounted for 77.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $531.36 | 77.5% | 17 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $53.08 | 7.7% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $45.82 | 6.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.81 | 2.7% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $18.69 | 2.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.78 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $685.54 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $194.29 | 6 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $194.29 | 6 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $112.62 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $71.13 | 1 | 2025 |
Source payment records
|
|||||
| VENACORE THROMBECTOMY CATHETER Normalized: venacore thrombectomy catheter |
Device | Stryker Corporation | $60.50 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $45.82 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $37.95 | 1 | 2025 |
Source payment records
|
|||||
| PROTRIEVE SHEATH Normalized: protrieve sheath |
Device | Stryker Corporation | $33.76 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| Denali Vena Cava Filter Normalized: denali vena cava filter |
Device | Bard Peripheral Vascular, Inc. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| INTHRILL THROMBECTOMY CATHETER Normalized: inthrill thrombectomy catheter |
Device | Stryker Corporation | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| EMBOLD Fibered Normalized: embold fibered |
Device | Boston Scientific Corporation | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Becton, Dickinson and Company | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| SPIDERFX Normalized: spiderfx |
Device | Medtronic, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 123 |
| Metformin Hcl | Metformin Hcl | 168 | 52 |
| Lisinopril | Lisinopril | 126 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 112 | 45 |
| Losartan Potassium | Losartan Potassium | 104 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 90 | 30 |
| Jardiance | Empagliflozin | 84 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 23 |
| Tramadol Hcl | Tramadol Hcl | 73 | 13 |
| Famotidine | Famotidine | 62 | 27 |
| Gabapentin | Gabapentin | 61 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 18 |
| Carvedilol | Carvedilol | 54 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 19 |
| Furosemide | Furosemide | 47 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 18 |
| Januvia | Sitagliptin Phosphate | 35 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 14 |
| Omeprazole | Omeprazole | 32 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Glipizide | Glipizide | 28 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $685.54 · 24 records | Stryker Corporation | ARTIX MT, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, Denali Vena Cava Filter, EMBOLD Fibered, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, INTHRILL THROMBECTOMY CATHETER, LUTONIX Drug Coated Balloon, PROTRIEVE SHEATH, RotarexS 6 F x 135 cm, SPIDERFX, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VENACORE THROMBECTOMY CATHETER | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error